Bausch Health Companies Inc. (BHC)
Best Value Stocks to Buy for September 22nd
BHC, OPHC and TRVG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 22nd, 2026.
Can Bausch (BHC) Run Higher on Rising Earnings Estimates?
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine
Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and enabling margin and EBITDA expansion without unsustainable revenue acceleration.
Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial
Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BHC Q2 Earnings Beat Estimates on Salix and Solta Growth, '26 View Raised
BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.
Bausch Health Companies Inc. (BHC) Q2 2026 Earnings Call Transcript
Bausch Health Companies Inc. (BHC) Q2 2026 Earnings Call Transcript
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates
Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago.
Bausch Health Cos Q2 Earnings Call Highlights
Bausch Health Cos NYSE: BHC reported second-quarter results that management said extended its streak of revenue and adjusted EBITDA growth to 13 consecutive quarters, driven by performance in its Salix, international and Solta Medical businesses.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
